🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for MRD

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma NCT06606028n/a1 site📍 San Francisco University of California, San Francisco · Tests: Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia NCT06184009Phase 29 sites📍 Seoul📍 Seoul📍 Incheon Jae Wook Lee · Tests: ALL, High risk Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance NCT06653062n/a1 site📍 Wuhan Tongji Hospital · Tests: Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD NCT05530096n/a1 site📍 Montreal Sir Mortimer B. Davis - Jewish General Hospital · Tests: Standard of care Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer NCT07214532NA49 sites📍 Phoenix📍 Scottsdale📍 Tucson Natera, Inc. · Tests: ctDNA-Guided Treatment Strategy Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML NCT04168502Phase 348 sites📍 Alessandria📍 Ancona📍 Ascoli Piceno Gruppo Italiano Malattie EMatologiche dell'Adulto · Tests: Gemtuzumab Ozogamicin Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy NCT05255354n/a1 site📍 Palo Alto Adaptive Biotechnologies · Tests: ClonoSEQ Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer NCT07057102n/a1 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… Motixafortide for MRD Sensitization in AML NCT07392970Phase 21 site📍 St Louis Washington University School of Medicine · Tests: Motixafortide Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease NCT06941389n/a37 sites📍 Birmingham📍 Birmingham📍 Wilmington University of Rochester Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT NCT03793517Phase 2, Phase 31 site📍 Beijing Peking University People's Hospital · Tests: Decitabine, mBU/CY and ATG, mBU/CY Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies NCT07211178n/a16 sites📍 Birmingham📍 Whittier📍 Weston Tempus AI · Tests: There are no interventions in this observational study. Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) NCT06005818Phase 21 site📍 Birmingham University of Alabama at Birmingham · Tests: Pembrolizumab injection Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML NCT06221683Phase 213 sites📍 Hefei📍 Hefei📍 Guangzhou Children's Hospital of Soochow University · Tests: Homoharringtonine, Cytarabine, Etoposide, Venetoclax, Mitoxantrone hydrochloride liposome A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS NCT05788679Phase 21 site📍 Stockholm Karolinska University Hospital · Tests: Azacitidine, Donor lymphocytes, Tapering of immune suppression Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD NCT07775950NA1 site📍 Guangzhou Sun Yat-sen University · Tests: Discontinue NA Treatment, Continued Immunotherapy, Observation CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. NCT06752785Phase 11 site📍 Guangzhou Guangzhou Women and Children's Medical Center · Tests: CAR-T Therapy CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT NCT07441291Phase 31 site📍 Beijing Peking University People's Hospital · Tests: CAR-T, DLI Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD NCT06511882Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Azacitidine, Decitabine, Venetoclax Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse NCT06910124Phase 21 site📍 Miami Dickran Kazandjian, MD · Tests: Linvoseltamab, Lenalidomide Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study NCT05987241Phase 2, Phase 3505 sites📍 Phoenix📍 Phoenix📍 Tucson National Cancer Institute (NCI) · Tests: Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients NCT06885476NA1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna · Tests: Infusion of alloreactive NK cells Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12) NCT05534087Phase 313 sites📍 Busan📍 Daegu📍 Goyang Seoul National University Hospital · Tests: mFOLFIRINOX-FOLFIRI intensified chemotherapy, FOLFOX or CAPOX adjuvant chemotherapy Tirzepatide Weight Loss for MRD+ Early Breast Cancer NCT06517212Phase 21 site📍 Dallas Baylor Research Institute · Tests: Tirzepatide MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma NCT07106736Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: BCMA CAR-T, GPRC5D/CD3 BiTEs Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma NCT06207799Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Elranatamab, Lenalidomide, Plerixafor, Melphalan, Busulfan A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD NCT07104058NA1 site📍 Beijing Luo Yaping · Tests: 68Ga-FAPI PET / CT Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma NCT06149910n/a1 site📍 Seattle All4Cure · Tests: Multiple Myeloma Pathway, All4Cure Platform, Documentation Pathway Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection NCT06409702Phase 41 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone, VRD for first-cycle induction therapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy